Solid Biosciences (SLDB) Liabilities and Shareholders Equity (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $422.9 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 22.97% year-over-year to $422.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (up 26.89% YoY), and the FY2025 full-year result was $232.5 million, up 23.26% from the prior year.
• Liabilities and Shareholders Equity grew to $422.9 million in Q1 2026, from $232.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $422.9 million in Q1 2026 to a low of $164.9 million in Q4 2023.
• A 5-year average of $241.6 million and a median of $229.6 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity slumped 36.62% in 2023 and jumped 38.29% in 2025, its largest moves.
• Tracing SLDB's Liabilities and Shareholders Equity over 5 years: stood at $260.3 million in 2022, then tumbled by 36.62% to $164.9 million in 2023, then climbed by 14.38% to $188.7 million in 2024, then advanced by 23.26% to $232.5 million in 2025, then soared by 81.86% to $422.9 million in 2026.
• Business Quant data shows SLDB's Liabilities and Shareholders Equity at $422.9 million in Q1 2026, $232.5 million in Q4 2025, and $273.9 million in Q3 2025.